Oncology

#Academic #AI / data analytics / healthtech / informatics #Analysis #Cellular & Molecular biology #Chemical engineering #Clinical specialities #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #In Silico Biology #Lead discovery #Molecular medicine #Oncology #Organic chemistry #Pharmacology #Regulatory #RNA #Sequencing

Mining Plant Genomes – A modern approach to herbal healing

Mining Plant Genomes - A modern approach to herbal healing By Michelle Vierra Plants are stationary soldiers. Rooted to one spot, they are not able to chase nutrients or flee from herbivores and pathogens. So in addition to the basic metabolites they synthesise for their survival, they produce a diverse… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Biochemistry #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Lead discovery #Molecular medicine #Oncology #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

From Genotype to Phenotype: Leveraging functional genomics in oncology

From Genotype to Phenotype: Leveraging functional genomics in oncology By Dr Menelas Pangalos & Steve Rees et al. A challenge in drug discovery is that, at best, only around one in five drug candidates will lead to the launch of a medicine. In 2011, AstraZeneca initiated a strategic ‘5R Framework’… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug development #Drug discovery #Flow Cytometry #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Imaging #Immunology #Lead discovery #Lead optimisation #Oncology #PCR #Preclinical #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Toxicology #Translational #Translational chemistry

3D Organoid Cell Culture: Optimising disease models for drug discovery

3D Organoid Cell Culture - Optimising disease models for research and drug discovery By Dr Amanda Linkous, Hilary Sherman, Iris Li and Dr Richard M. Eglen The use of human-induced pluripotent stem cells (HiPSCs) continues to grow in three-dimensional (3D) spheroid and organoid culture. Although advances in 3D cell culture… Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development optimisation & technology #Automation / robotics #Biochemistry #Bioengineering #Biomarkers #Business #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug repositioning #Drug targets #Gene therapy #Genetics / genomics #High Content Screening #High throughput screening #Immunology #Lead discovery #Lead optimisation #Medicinal chemistry #Molecular medicine #Nanomedicine / nanotechnology #Oncology #Organic chemistry #Pathology #Pharmacology #Pharmokinetics #Precision medicine #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Toxicology #Translational #Translational chemistry

Systems Pharmacology: When multi-targeting is advantageous

Systems Pharmacology: When multi-targeting is advantageous By Dr Kirkwood A. Pritchard Jr, Dr Dustin P. Martin and Dr Stephen Naylor The safety and efficacy of therapeutic drugs still requires improvement. In part this is due to the promiscuity of individual drugs, which on average can interact with an estimated 6-28… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development optimisation & technology #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #High throughput screening #Imaging #Lead discovery #Lead optimisation #Molecular medicine #Oncology #Organic chemistry #Pathology #Pharmacology #Preclinical #Protein chemistry / Proteomics #RNA #Screening #Stem cells #Target validation #Therapeutics #Toxicology

Increasing Drug Discovery Success With 3D Cell Culture Systems

Increasing Drug Discovery Success With 3D Cell Culture Systems By Dr Richard M. Eglen, Dr Feng Li and Dr Tony Frutos Drug candidates often fail in the clinic for two reasons: they lack efficacy or possess an adverse toxicity profile. These failures can come at a high cost, especially when… Read More

#Archive

#Academic #Biologics / Biotechnology #Biomarkers #Business #Cell culture #Cell therapy #Cellular & Molecular biology #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene therapy #Genomics #High Content Screening #Immunology / Virology & Vaccines #Lead discovery #Lead optimisation #Medicinal chemistry #Molecular medicine #Oncology #Preclinical #RNA #Therapeutics #Translational #Translational chemistry

Therapeutics Discovery at MD Anderson – Making Patients a Priority During Drug Development

By Dr Phil Jones The mission at The University of Texas MD Anderson Cancer Center is to eradicate cancer, which remains a major cause of mortality worldwide. It is the second leading cause of death in the United States and globally, claiming more lives than malaria, HIV/AIDs and tuberculosis combined… Read More

#Archive

#Academic #Animal models #Assay development optimisation & technology #Business #Cell therapy #Cellular assays #Chemistry #Drug development #Drug discovery #Gene editing #Gene therapy #Genetics #Genetics / genomes #High Content Screening #Immunology #Lead discovery #Oncology #Patent Law #Preclinical #RNA #Stem cells #Therapeutics

Genetically-Engineered Models: The Value of Precious GEMs

Genetically-Engineered Models: The Value of Precious GEMs By Dr Megan M. MacBride Genetically-engineered animal models (GEMs) are critical tools for drug discovery and development, but intellectual property (IP) concerns can complicate access. As pharma and biotech increasingly outsource R&D activities to universities, careful scrutiny is required to ensure adherence to… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Biochemistry #Business #Cell therapy #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Immunology #Immunology / Virology & Vaccines #Lead discovery #Molecular medicine #Oncology #Protein chemistry / Proteomics #Regenerative Medicine #RNA #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

Current Trends in RNA Therapeutics Development

Current Trends in RNA Therapeutics Development By Dr Xiaoqiu Wu and Dr Andrew P. Turnbull Cellular RNAs play crucial roles during disease progression and represent a diverse and largely untapped class of biomolecules that can be exploited for drug development. RNA species include messenger RNAs (mRNAs) that are translated into… Read More

#Exclusive Content

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Animal models #Automation / robotics #Biochemistry #Bioengineering #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Genetics #High Content Screening #High throughput screening #Imaging #In Silico Biology #Lead discovery #Mass spectrometry / NMR #Medicinal chemistry #Molecular medicine #Oncology #Organic chemistry #Pathology #PCR #Pharmacology #Preclinical #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Toxicology #Translational #Translational chemistry

Cutting-edge technologies meet traditional paradigms in assay development

The Future Of Drug Discovery - Cutting-edge technologies meet traditional paradigms in assay development By Dr Roger Bosse With more than 1,500 drugs approved by the Food and Drug Administration (FDA) on the market, the easiest disease targets are already covered (1). Today’s scientists are challenged to find new compounds,… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Automation / robotics #Biochemistry #Biologics / Biotechnology #Biomarkers #Business #Cell therapy #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug targets #Gene therapy #Genomics #Immunology #Immunology / Virology & Vaccines #In Silico Biology #Lead discovery #Molecular medicine #Oncology #Orphan drugs #Patent Law #Pharmacology #Precision medicine #Preclinical #Regenerative Medicine #Regulatory #RNA #Stem cells #System biology #Systems biology #Target validation #Therapeutics

Integrated Platform Drug Discovery and Development Companies – Part 1

Integrated Platform Drug Discovery and Development Companies - Part 1 By Dr Urban A. Kiernan and Dr Stephen Naylor Technology was lauded as the saviour of the drug discovery and development (DDD) process during the late 1990s. A myriad of independent companies developed and offered ‘innovative’ tools, technologies and platforms… Read More

#Archive

#Analysis #Assay development optimisation & technology #Biomarkers #Business #Cell culture #Cellular & Molecular biology #Cellular assays #Clinical specialities #Drug development #Drug discovery #Drug targets #Gene editing #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Lead discovery #Molecular medicine #Oncology #Precision medicine #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology

How Phenotypic CRISPR Screening is Revolutionising Drug Discovery

How Phenotypic CRISPR Screening is Revolutionising Drug Discovery By Dr Steffen Lawo and Dr Carlos le Sage Research in drug discovery and biotechnology increasingly exploits gene editing at industrial scale in order to identify and validate new biological targets for precision medicines. The discovery of CRISPR-Cas9 systems has fuelled a… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Bioengineering #Business #Cell / tissue culture #Cell culture #Cellular assays #Chemical engineering #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Genetics / genomes #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Oncology #Precision medicine #Preclinical #Regenerative Medicine #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Toxicology #Translational #Translational chemistry

Induced Pluripotent Stem Cells (iPSCs) – Unlocking their full potential

Induced Pluripotent Stem Cells (iPSCs) - Unlocking their full potential for Drug Discovery By Abby Edwards and Dr Richard Massey Human stem cells were once viewed primarily as regenerative materials for tissue repair through cell therapies. However, advances in technologies and protocols mean that induced pluripotent stem cells (iPSCs) are… Read More

#Archive

#Academic #Analysis #Business #Cell / tissue culture #Cell culture #Cell therapy #Clinical trials #Drug development #Drug discovery #Enabling technologies #Gene therapy #High throughput screening #Lead discovery #Microbiology #Molecular medicine #Oncology #Precision medicine #Regenerative Medicine #RNA #Screening #Stem cells #System biology #Systems biology

Cell Therapy – Preserving Cell Integrity and Viability To Drive Discovery

Cell Therapy - Preserving Cell Integrity and Viability To Drive Discovery Mary Kay Bates Cell therapy is poised to play a pivotal role in the development of precision and personalised medicines that will transform healthcare for millions of patients worldwide. Involving the direct use of whole cells or cellular material… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Biochemistry #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Gene therapy #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Imaging #In Silico Biology #Lead discovery #Lead optimisation #Mass spectrometry / NMR #Medicinal chemistry #Molecular medicine #Oncology #Pharmacology #Preclinical #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Toxicology #Translational #Translational chemistry

Astrazeneca R&D – Improving Drug Development Productivity With Better Predictivity

Astrazeneca R&D - Improving Drug Development Productivity With Better Predictivity By Dr Menelas Pangalos & Steve Rees et al. Changing demands in global healthcare over the past 15 years have led to greater complexity and spiralling costs in drug development. The average price tag of taking a new drug from… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Automation / robotics #Biochemistry #Biomarkers #Business #Cell therapy #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug repositioning #Drug targets #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Immunology #Lead discovery #Molecular medicine #Nanomedicine / nanotechnology #Oncology #Pharmacogenomics #Pharmacology #Precision medicine #Protein chemistry / Proteomics #QA/QC #Regulatory #RNA #Screening #Sequencing #System biology #Systems biology

Precision Medicine Drugs – Pleonasm or Reality?

Precision Medicine Drugs - Pleonasm or Reality? Dr Urban Kiernan and Dr Stephen Naylor The complexity and uniqueness of human metabolism and physiology in the past decade has been highlighted and dissected. Arguments have been made to suggest that our lack of understanding about human individuality has led to the… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Biologics / Biotechnology #Biomarkers #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Clinical trials #Drug development #Drug discovery #Drug targets #Gene editing #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Immunology #Immunology / Virology & Vaccines #Lead discovery #Microbiome #Molecular medicine #Oncology #Preclinical #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Therapeutics #Toxicology #Translational #Translational chemistry

Bringing Immuno-Oncology Together: How An Immunologist & Oncologist Collaborate

Bringing Immuno-Oncology Together: How An Immunologist & Oncologist Collaborate By Dr Julia Schuler and Dr Louise Brackenbury For many years, immunology and oncology operated as separate disciplines within drug discovery. However, recent advances in immuno-oncology (IO) have demonstrated what can be achieved when the two disciplines join forces in developing… Read More

#Archive